Cart
sales@molnova.com
6-(Dimethylamino)purine
CAS No. 938-55-6
6-(Dimethylamino)purine( NN-Dimethyladenine )
Catalog No. M20829 CAS No. 938-55-6
6-(Dimethylamino)purine is a serine threonine protein kinase and CDK inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 27 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name6-(Dimethylamino)purine
-
NoteResearch use only, not for human use.
-
Brief Description6-(Dimethylamino)purine is a serine threonine protein kinase and CDK inhibitor.
-
Description6-(Dimethylamino)purine is a serine threonine protein kinase and CDK inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsNN-Dimethyladenine
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK|serine threonine protein kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number938-55-6
-
Formula Weight163.18
-
Molecular FormulaC7H9N5
-
Purity>98% (HPLC)
-
SolubilityDMSO:32mg/mL(196.1mM)
-
SMILESCN(C)c1ncnc2[nH]cnc12
-
Chemical Name6-Dimethylaminopurine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nakashima M Cui Z G Tabuchi Y et al. Apoptosis induced by an alkylated purine 6-dimethylaminopurine and changes in gene expression in human lymphoma U937 cells[J]. Anticancer research 2008 28(2A):609-620.
molnova catalog
related products
-
PF-562271
PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays.
-
Purvalanol A
A potent, cell-permeable, selective inhibitor of CDK with IC50s of 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively.
-
23-epi-26-Deoxyactei...
23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
